Novartis Ag (NVS) Other financing activities (2009 - 2026)
Novartis Ag recorded quarterly Other financing activities of $78.0 million in Q1 2026, up 336.36% quarter-over-quarter from -$33.0 million in Q4 2025, and up 239.13% year-over-year from $23.0 million in Q1 2025.
Novartis Ag's Other financing activities history runs 18 years deep, the most recent figure standing at $78.0 million for Q1 2026.
- In Q1 2026, Other financing activities rose 239.13% year-over-year to $78.0 million; the TTM figure through Mar 2026 stood at -$148.0 million (down 223.33% YoY), while the FY2025 annual figure was -$203.0 million, down 336.05% from the prior year.
- Other financing activities came in at $78.0 million for Q1 2026 at Novartis Ag, up from -$33.0 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $78.0 million in Q1 2026 to a low of -$215.0 million in Q2 2025.
- A 5-year average of -$23.5 million and a median of $22.0 million in 2022 frame the typical range for Other financing activities.
- On a YoY basis, Other financing activities climbed as much as 2600.0% in 2022 and fell as far as 2783.33% in 2022.
- Novartis Ag's Other financing activities stood at -$161.0 million in 2022, then surged by 31.06% to -$111.0 million in 2023, then surged by 125.23% to $28.0 million in 2024, then tumbled by 217.86% to -$33.0 million in 2025, then soared by 336.36% to $78.0 million in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $78.0 million, -$33.0 million, and $22.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78.00 Mn |
| Mar 31, 2026 | 78.00 Mn |
| Dec 31, 2025 | -33.00 Mn |
| Dec 31, 2025 | -33.00 Mn |
| Sep 30, 2025 | 22.00 Mn |
| Sep 30, 2025 | 22.00 Mn |
| Jun 30, 2025 | -215.00 Mn |
| Jun 30, 2025 | -215.00 Mn |
| Mar 31, 2025 | 23.00 Mn |
| Mar 31, 2025 | 23.00 Mn |
| Dec 31, 2024 | 28.00 Mn |
| Dec 31, 2024 | 28.00 Mn |
| Sep 30, 2024 | 47.00 Mn |
| Sep 30, 2024 | 47.00 Mn |
| Jun 30, 2024 | 22.00 Mn |
| Jun 30, 2024 | 22.00 Mn |
| Mar 31, 2024 | -11.00 Mn |
| Mar 31, 2024 | -11.00 Mn |
| Dec 31, 2023 | -111.00 Mn |
| Dec 31, 2023 | -111.00 Mn |
| Sep 30, 2023 | 24.00 Mn |
| Sep 30, 2023 | 24.00 Mn |
| Jun 30, 2023 | -35.00 Mn |
| Jun 30, 2023 | -35.00 Mn |
| Mar 31, 2023 | -206.00 Mn |
| Mar 31, 2023 | -206.00 Mn |
| Dec 31, 2022 | -161.00 Mn |
| Dec 31, 2022 | -161.00 Mn |
| Sep 30, 2022 | 32.00 Mn |
| Sep 30, 2022 | 32.00 Mn |
| Jun 30, 2022 | 75.00 Mn |
| Jun 30, 2022 | 75.00 Mn |
| Mar 31, 2022 | 22.00 Mn |
| Mar 31, 2022 | 22.00 Mn |
| Dec 31, 2021 | 6.00 Mn |
| Dec 31, 2021 | 6.00 Mn |
| Jun 30, 2021 | -3.00 Mn |
| Jun 30, 2021 | -3.00 Mn |
| Mar 31, 2021 | -11.00 Mn |
| Mar 31, 2021 | -11.00 Mn |
| Dec 31, 2020 | -13.00 Mn |
| Dec 31, 2020 | -13.00 Mn |
| Sep 30, 2020 | 19.00 Mn |
| Sep 30, 2020 | 19.00 Mn |
| Jun 30, 2020 | -13.00 Mn |
| Jun 30, 2020 | -13.00 Mn |
| Mar 31, 2020 | -13.00 Mn |
| Mar 31, 2020 | -13.00 Mn |
| Dec 31, 2019 | -22.00 Mn |
| Dec 31, 2019 | -22.00 Mn |
| Sep 30, 2019 | -20.00 Mn |
| Sep 30, 2019 | -20.00 Mn |
| Jun 30, 2019 | 532.00 Mn |
| Jun 30, 2019 | 532.00 Mn |
| Mar 31, 2019 | -461.00 Mn |
| Mar 31, 2019 | -461.00 Mn |
| Dec 31, 2018 | -350.00 Mn |
| Dec 31, 2018 | -350.00 Mn |
| Sep 30, 2018 | -155.00 Mn |
| Sep 30, 2018 | -155.00 Mn |
| Jun 30, 2018 | -262.00 Mn |
| Jun 30, 2018 | -262.00 Mn |
| Mar 31, 2018 | -53.00 Mn |
| Mar 31, 2018 | -53.00 Mn |
| Dec 31, 2017 | -40.00 Mn |
| Dec 31, 2017 | -40.00 Mn |
| Sep 30, 2017 | 37.00 Mn |
| Sep 30, 2017 | 37.00 Mn |
| Jun 30, 2017 | 82.00 Mn |
| Jun 30, 2017 | 82.00 Mn |
| Mar 31, 2017 | -69.00 Mn |
| Mar 31, 2017 | -69.00 Mn |
| Dec 31, 2016 | 10.00 Mn |
| Dec 31, 2016 | 10.00 Mn |
| Sep 30, 2016 | -8.00 Mn |
| Sep 30, 2016 | -8.00 Mn |
| Jun 30, 2016 | 34.00 Mn |
| Jun 30, 2016 | 34.00 Mn |
| Mar 31, 2016 | -29.00 Mn |
| Mar 31, 2016 | -29.00 Mn |
| Dec 31, 2015 | 29.00 Mn |
| Dec 31, 2015 | 29.00 Mn |
| Sep 30, 2015 | 7.00 Mn |
| Sep 30, 2015 | 7.00 Mn |
| Jun 30, 2015 | 152.00 |
| Jun 30, 2015 | 152.00 |
| Mar 31, 2015 | -192.00 |
| Mar 31, 2015 | -192.00 |
| Sep 30, 2014 | -38.00 |
| Sep 30, 2014 | -38.00 |
| Jun 30, 2014 | -25.00 |
| Jun 30, 2014 | -25.00 |
| Mar 31, 2014 | -78.00 |
| Mar 31, 2014 | -78.00 |
| Dec 31, 2013 | -65.00 |
| Dec 31, 2013 | -65.00 |
| Sep 30, 2013 | -21.00 |
| Sep 30, 2013 | -21.00 |
| Jun 30, 2013 | 131.00 |
| Jun 30, 2013 | 131.00 |
| Mar 31, 2013 | -148.00 |
| Mar 31, 2013 | -148.00 |
| Sep 30, 2012 | -26.00 |
| Sep 30, 2012 | -26.00 |
| Jun 30, 2012 | 99.00 |
| Jun 30, 2012 | 99.00 |
| Mar 31, 2012 | -126.00 |
| Mar 31, 2012 | -126.00 |
| Dec 31, 2011 | -79.00 |
| Dec 31, 2011 | -79.00 |
| Sep 30, 2011 | -84.00 |
| Sep 30, 2011 | -84.00 |
| Jun 30, 2011 | -12.00 |
| Jun 30, 2011 | -12.00 |
| Mar 31, 2011 | -24.00 |
| Mar 31, 2011 | -24.00 |
| Dec 31, 2010 | -11.00 |
| Dec 31, 2010 | -11.00 |
| Sep 30, 2010 | -4.00 |
| Sep 30, 2010 | -4.00 |
| Jun 30, 2010 | 82.00 |
| Jun 30, 2010 | 82.00 |
| Mar 31, 2010 | -112.00 |
| Mar 31, 2010 | -112.00 |
| Dec 31, 2009 | -14.00 |
| Dec 31, 2009 | -14.00 |
| Sep 30, 2009 | 5.00 |
| Sep 30, 2009 | 5.00 |
| Jun 30, 2009 | 78.00 |
| Jun 30, 2009 | 78.00 |
| Mar 31, 2009 | -82.00 |
| Mar 31, 2009 | -82.00 |